Projected impact of population-level multi-cancer early detection screening: a discrete event simulation analysis

Clicks: 10
ID: 331701
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #319 of 380 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 380 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Cancer screening for multiple cancers simultaneously, rather than one cancer at a time, has emerged as a promising strategy for population-level cancer screening, largely driven by the advent and rapid development of liquid biopsy-based multi-cancer early detection (MCED) tests. However, their potential impact on mortality across cancer types remains incompletely characterized. We developed a patient-level, cross-cohort discrete event simulation model calibrated to SEER age-specific incidence for ages 18-80 across 1939-2001 birth cohorts for ten cancers, stratified by sex and race (non-Hispanic White and Black). Early detection benefit was modeled by shifting cancers to localized disease and advancing detection by literature-derived sojourn times, under detection sensitivities from 10% to 100%. The multicancer natural history model achieved calibration for all ten cancers, with modeled incidence closely approximating SEER-observed incidence. Under ideal early detection, pooled cancer mortality fell by 41.0%, from 6.42% to 3.79% of the simulated population, with similar proportional reductions across sex-race strata (39.9% to 43.9%). The largest site-specific reductions occurred for prostate cancer in males and ovarian cancer in females, while liver and bladder cancers benefited least. Overdiagnosis ranged from 10.9% to 28.9%, with lung cancer highest. Our MCED framework projects population-level mortality reduction from early multi-cancer detection. Under ideal screening conditions, cancer mortality benefits varied by cancer type, reflecting differences in both the length of the preclinical detectable window and survival at localized stage. This calibrated multicancer model provides a flexible framework for evaluating MCED blood tests as clinical trial data on test performance become available.
Reference Key
openalex_W7220655474 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Nitish Aswani, Jiheum Park, Francesca Lim, Matthew T. Prest, Jennifer S. Ferris, Jeong Yun Yang, Liyuan Gong, Stella K. Kang, Chin Hur
Journal JNCI Journal of the National Cancer Institute
Year 2026
DOI
10.1093/jnci/djag356
URL
https://doi.org/10.1093/jnci/djag356
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.